Sibel Health appears in FDA premarket records as the applicant for multiple ANNE-branded devices reviewed under the 510(k) pathway. The most recent entry in the linked collection is ANNE Limb, cleared as substantially equivalent on November 5, 2026 under K261870, with a decision date recorded in the FDA device database. Earlier clearances in the numbered sources cover ANNE Limb under K240305 and the ANNE View, Central Hub under K242842. The company’s own published pages describe the ANNE Limb sensor’s sensing capabilities and materials, while a PLOS Digital Health article describes a wireless pediatric monitoring platform. [1][4][9][3][8]

The 2026 ANNE Limb clearance

FDA records for K261870 list Sibel Health as applicant and ANNE Limb as the device name, with product code DQA, advisory committee Cardiovascular, regulation number 870.2700 for Oximeter, and Class II designation. The submission was received June 4, 2026 and decided November 5, 2026 with decision code SESE, described as substantially equivalent, under a traditional clearance type with a summary statement. The filing address given is in Chicago, Illinois. [1]

The linked collection for this company contains one 510(k) record, and that record’s decision is SESE. That count reflects the linked filings as retrieved, not the company’s total regulatory history or commercial position. [1]

Earlier ANNE Limb and ANNE View filings

An FDA clearance letter dated May 28, 2024 addresses Sibel Health Inc. regarding K240305 for trade name ANNE Limb, citing regulation 21 CFR 870.2700 (Oximeter), Class II, and product codes DQA and FLL. The letter states the submission was dated and received May 7, 2024. A separate FDA letter dated January 8, 2025 addresses K242842 for trade name ANNE View, Central Hub, citing 21 CFR 870.2300 (Cardiac Monitor, including cardiotachometer and rate alarm), Class II, and product codes MSX, MWI, KMI and DRG, with the submission dated and received December 9, 2024. [4][9]

The K242842 documentation describes the ANNE View application as intended for display of physiological data from the ANNE Chest and ANNE Limb devices, communicating with compatible medical devices over Bluetooth, with the Central Hub receiving data. The same document lists visual and auditory alarms and an operating system comparison against a Windows-based central hub desktop. [9]

Documented device features

Sibel Health’s published ANNE Limb page describes the sensor as a clinical-grade monitoring device measuring SpO2, pulse rate and skin temperature, rechargeable and transmitting data in real time. The page lists temperature sensing from 23 to 43°C, battery life of 36 hours, biocompatible medical-grade silicone as the device material and biocompatible medical foam adhesive. These are manufacturer statements about the product, not independently verified performance results. [3]

The company’s home page states a mission to deliver “Better Health Data for All” and lists focus areas spanning discovery, clinical trials and research, adult and pediatric clinical care, and adult remote patient monitoring, with ANNE-branded offerings named in those categories. A PLOS Digital Health research article describes a wireless neurological and cardiopulmonary monitoring platform for pediatrics, including EEG power spectra figures; the numbered excerpt does not show author affiliations. [7][8]

Identity and scope notes

Across the numbered FDA records, the applicant name is Sibel Health or Sibel Health Inc., and the Chicago address appears in filing correspondence. That address is a regulatory filing address and should not be read as a verified headquarters. The company’s published pages separately list a Sibel Korea location in Seoul alongside a Chicago address. [1][4][5]

The documented products in these sources are the ANNE Limb sensor and the ANNE View application with Central Hub, each tied to specific 510(k) numbers and regulation citations. No sales figures, installed base, customer list, certifications or clinical outcome data appear in the numbered sources, and none are asserted here. [1][4][9]